Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 20/20 | 0.71 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3891068 | 0.87 | F2 (0.68) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL3899630 | 0.87 | F2 (0.65) | F2PRSS1 | |
| SCHEMBL13804076 | 0.84 | F2 (0.67) | F2 | |
| SCHEMBL13804242 | 0.84 | F2 (0.67) | F2 | |
| SCHEMBL3890309 | 0.84 | F2 (0.67) | F2 | |
| SCHEMBL5771919 | 0.82 | F2 (0.56) | F2 | |
| SCHEMBL3890210 | 0.81 | F2 (1.00) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL3889779 | 0.80 | F2 (0.78) | F2 | |
| SCHEMBL3890682 | 0.79 | F2 (1.00) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL3890638 | 0.79 | F2 (0.75) | F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550474-B2 | Substituted phenyl acetamides and their use as protease inhibitors | JOHNSON & JOHNSON PHARMACEUTICALS RESEARCH & DEVELOPMENT, L.L.C. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1613319-B1 | SUBSTITUTED PHENYL ACETAMIDES AND THEIR USE AS PROTEASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1613319-A2 | SUBSTITUTED PHENYL ACETAMIDES AND THEIR USE AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20040254166-A1 | Substituted phenyl acetamides and their use as protease inhibitors | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C. | 2004-12-16 | — | — | US | disclosed |
| WO-2004091613-A2 | SUBSTITUTED PHENYL ACETAMIDES AND THEIR USE AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254166-A1 | Substituted phenyl acetamides and their use as protease inhibitors | TFPI, F12, SPINT2 | F2 13/4885PRSS1 7/4885PRSS2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.